Piper Sandler Maintains a Buy on Taysha Gene Therapies (TSHA), Sets a PT of $9

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) is one of the top strong buy stocks under $5 to buy now. Piper Sandler analyst Biren Amin maintained a Buy rating on Taysha Gene Therapies, Inc. (NASDAQ:TSHA) on August 18, setting a price target of $9.00.

Is Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) the Best Bet in Gene Therapy Industry?

A laboratory technician preparing a gene therapy sample in a sterile environment.

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) announced its fiscal Q2 2025 results on August 12, reporting $312.8 million in cash and cash equivalents as of June 30.

Management stated that this reflects the “gross proceeds of $230.0 million from the May 2025 follow-on financing, including full exercise of the underwriters’ option to purchase additional shares”.

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) expects its current cash resources to support its planned operating expenses and capital requirements into 2028.

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) is a clinical-stage biotechnology company that develops and commercializes adeno-associated virus (AAV) based gene therapies to treat monogenic diseases of the central nervous system.

While we acknowledge the potential of TSHA to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than TSHA and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.